Diagnostic Center | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Subscribe To Our Newsletter & Stay Updated
